The Ministry
of Health of the Czech Republic (MoH) has issued a decision confirming the
classification of medicinal products containing gliflozins as a group of
essentially therapeutically interchangeable medicinal products for the
treatment of type 2 diabetes mellitus (T2DM). This decision upheld the original
contested ruling of the State Institute for Drug Control (SÚKL).
Gliflozins
are used...
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of pharmaceutical and medical device information. We also offer flexible services that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you need expert guidance.
Our knowledge, your opportunity.
